Protagonist Therapeutics Virtual KOL Event following ASH

Protagonist Therapeutics Virtual KOL Event following ASH

VIRTUAL, December 9, 2020

Please join Protagonist Therapeutics management for a Virtual KOL Event following the presentation of PTG-300 data in Polycythemia Vera at the ASH Annual Meeting.

Date: Wednesday, December 9th

Time: 8:30-9:30am ET
Dial-In Details: 1-844-515-9178 (U.S./Canada), 1-614-999-9313 (International) and refer to Conference ID number 8794865. A live and archived webcast will also be accessible in the Investors section of the Company’s website at www.protagonist-inc.com

Featured KOL Speaker: Andrew Kuykendall, M.D., PTG-300 study investigator and member of the Department of Malignant Hematology at the Moffitt Cancer Center

Additional information on Protagonist’s oral and poster presentations at ASH can be found here.

Please RSVP to Rebecca John rjohn@troutgroup.com or Alexandra Roy aroy@troutgroup.com

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Protagonist Therapeutics [PTGX] US$889 MM MCap
Pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op oral tar­get­ed ther­a­py-based drugs and in­jecta­bles for rare dis­eas­es. PTG-300 in­jectable hep­cidin mimet­ic Ph 2 trials on­go­ing in po­ly­cythemia ve­ra and hered­i­tary he­mochro­ma­to­sis; pos­i­tive up­dat­ed Ph 2 re­sults in PV pre­sent­ed at ASH 2020. PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis study sites ac­ti­vat­ed; PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist Ph 2 Crohn’s dis­ease study on­go­ing. [more in­for­ma­tion]